Labeesity®

Labeesity®
Product Description

Labeesity SFK7® is a standardized extract derived from Labisia pumila, a traditional herb native to Southeast Asia. It has gained recognition as a potential dietary ingredient due to its various health benefits. Notably, SFK7® has obtained approval as a New Dietary Ingredient from the US Food and Drug Administration (FDA) and has also re ceived recognition as a Novel Food from the European Food Safety Authority (EFSA). SFK7® has progressed to Phase 2 randomized controlled trials (RCTs) that specifically target obesity in Malaysia and Indonesia. The successful completion of Phase 2 RCTs in these countries suggests positive outcomes and supports the potential use of SFK7® for managing obesity.

Read more Show less

Medika Natura Sdn Bhd

  • Country/Region:
    Malaysia
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less
Specifications
  • Details
    SFK7® is a standardized extract derived from Labisia pumila, a traditional herb native to Southeast Asia. It has gained recognition as a potential dietary ingredient due to its various health benefits. Notably, SFK7® has obtained approval as a New Dietary Ingredient from the US Food and Drug Administration (FDA) and has also received recognition as a Novel Food from the European Food Safety Authority (EFSA).

    Extensive pre-clinical studies have been conducted on SFK7® to explore its potential in addressing obesity, diabetes, and cancer. These studies involved laboratory testing and animal models, examining the effects of SFK7® on these health conditions. The results of these pre-clinical studies have shown promising outcomes, indicating the potential therapeutic properties of SFK7® in managing obesity, diabetes, and cancer.
  • Selling Points
    Cardiovascular Health; Immune Health; Extensive pre-clinical studies have been conducted on SFK7® to explore its potential in addressing obesity, diabetes, and cancer. These studies involved laboratory testing and animal models, examining the effects of SFK7® on these health conditions. The results of these pre-clinical studies have shown promising outcomes, indicating the potential therapeutic properties of SFK7® in managing obesity, diabetes, and cancer.

    Furthermore, SFK7® has progressed to Phase 2 randomized controlled trials (RCTs) that specifically target obesity in Malaysia and Indonesia. The successful completion of Phase 2 RCTs in these countries suggests positive outcomes and supports the potential use of SFK7® for managing obesity.

    Currently, SFK7® is in the process of conducting Phase 3 studies in Malaysia, which is being carried out in conjunction with the submission of an IND (Investigational New Drug) application to the US FDA.
  • Model
    Standardized Extract Labisia pumila (SFK7®)
  • Supplied from
    Malaysia
  • Measured In
    milligram
More specifications Fewer specifications
Sales Markets
Show more Show less

Medika Natura Sdn Bhd

  • Country/Region:
    Malaysia
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile

More Products from Medika Natura Sdn Bhd (2)

  • Pervira®

    Product Pervira®

    Pervira® is a standardized extract derived from Kaempferia parviflora, a plant known for its medicinal properties. One of the key active components in Pervira® is 5,7-Dimethoxyflavone (5,7-DMF), which is present in a concentration of not less than 8%. The extract undergoes a standardized extraction pr...
  • Starpril®

    Product Starpril®

    Starpril® is a standardized extract derived from Orthosiphon stamineus, a medicinal plant known for its various therapeutic properties. The main active constituent of Starpril is Rosmarinic Acid, which has been identified as the primary compound responsible for its beneficial effects.